Read the original article here.

Halifax, Nova Scotia, October 3, 2018 – Sona Nanotech Inc. (CSE: SONA) (“Sona” or the “Company”) is pleased to announce that the Canadian Securities Exchange (CSE) has approved the Company’s application to list its common shares on the CSE.  Effective October 4, 2018, the Company’s shares will commence trading on the CSE under the symbol “SONA”.

Overview of Sona

Sona is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.

Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nano technologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.

The Amalgamation

Pursuant to the terms of an Amalgamation, every four (4) common shares of Stockport Exploration Inc. were exchanged for one (1) common share of Sona Nanotech Ltd. (the “Sona Shares”); and every 1.5802 common shares of Sona Nanotech Ltd. were exchanged for one (1) Sona Share.  The amalgamation was completed on August 8, 2018.

Stockport Exploration Inc. voluntarily delisted its common shares from the TSX Venture Exchange on August 7, 2018, and filed an application for listing its common shares on the CSE.

For More Information

For more information about Sona, please contact:

Darren Rowles
President and Chief Executive Officer
Telephone: (902) 442-0653
Email: darren@sonanano.com

2015 © Copyright - Bionova